Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles

Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles

ABSTRACTExtracellular vesicles (EVs) are promising tools for drug delivery across different biological barriers. Here, we evaluated the potential of EVs-mediated delivery of CD38 siRNA on the immunosuppression of hepatocellular carcinoma (HCC). EVs were isolated from bone marrow mesenchymal stem cel...

Full description

Bibliographic Details
Main Authors:	Jun Deng, Hui Ke
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	OncoImmunology
Subjects:	Hepatocellular carcinoma resistance CD38 siRNA extracellular vesicles macrophages PD-1/PD-L1 inhibitor
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2022.2152635

Similar Items

PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation
by: Jesus Pacheco-Torres, et al.
Published: (2021-02-01)

PD-1-siRNA Delivered by Attenuated Salmonella Enhances the Antitumor Effect of Chloroquine in Colon Cancer
by: Shuya Lu, et al.
Published: (2021-07-01)

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
by: Simona Serratì, et al.
Published: (2022-01-01)

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma
by: Simona Serratì, et al.
Published: (2023-09-01)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
by: Federica Costa, et al.
Published: (2021-01-01)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
by: Christie P. M. Verkleij, et al.
Published: (2020-12-01)

Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions
by: Raweewan Thiramanas, et al.
Published: (2020-09-01)

Extracellular vesicles recovered from plasma of severe dengue patients induce CD4+ T cell suppression through PD-L1/PD-1 interaction
by: Sharda Kumari, et al.
Published: (2023-12-01)

siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
by: Jae Yun Jung, et al.
Published: (2021-10-01)

Construction of PEI‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer
by: Guixue Yang, et al.
Published: (2022-11-01)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
by: Surbhi Mishra, et al.
Published: (2022-10-01)

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma
by: Junwei Kang, et al.
Published: (2022-10-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01)

A targeted siRNA‐loaded PDL1‐exosome and functional evaluation against lung cancer
by: Xianbin Lin, et al.
Published: (2022-06-01)

Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials
by: Wu Ye, et al.
Published: (2021-09-01)

Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma
by: Ji-Wei Li, et al.
Published: (2021-01-01)

Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma
by: Liwei Shao, et al.
Published: (2022-12-01)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-04-01)

Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma
by: WANG Yixin, et al.
Published: (2020-04-01)

The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice
by: Leilei Liang, et al.
Published: (2018-12-01)

Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1
by: Eun-Ji Choe, et al.
Published: (2022-08-01)

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients
by: Zeinab Rajabian, et al.
Published: (2019-03-01)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023-02-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
by: Yuhua Wei, et al.
Published: (2022-01-01)

Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
by: Jiaxing Liu, et al.
Published: (2022-01-01)

PD‐L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD‐L1‐low and ‐negative patients with non‐small cell lung cancer
by: Nadja Schöne, et al.
Published: (2024-03-01)

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8<sup>+</sup> T Cell Response in Hepatocellular Carcinoma
by: Julia Peña-Asensio, et al.
Published: (2021-04-01)

Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells
by: Simona Camorani, et al.
Published: (2022-10-01)

Predicting effect of anti-PD-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS
by: Botong Liu, et al.
Published: (2024-04-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
by: Yongkang Xu, et al.
Published: (2022-09-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

Elevation of spermine remodels immunosuppressive microenvironment through driving the modification of PD-L1 in hepatocellular carcinoma
by: Hong-Xiang Shi, et al.
Published: (2022-11-01)

Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2023-01-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)